Finanzen von Imunon Inc (IMNN)IMNNImunon Inc

Evaluating the bottom line, Imunon Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -641.03%, provide a clear picture of how effectively IMNN converts its operational activities into shareholder value.

In the context of the broader market, IMNN competes directly with industry leaders such as TRAW and EVGN. With a market capitalization of $8.75M, it holds a significant position in the sector. When comparing efficiency, IMNN's gross margin of N/A stands against TRAW's N/A and EVGN's 40.63%. Such benchmarking helps identify whether Imunon Inc is trading at a premium or discount relative to its financial performance.

Despite reporting a net loss of $2.8 million in Q2 2026, the company has shown a commitment to controlling expenses, with R&D costs at $1.5 million and a decrease in administrative costs. The forward P/E ratio is 16.78, suggesting potential for future profitability as clinical trials progress.